11 September 2015 - In final draft guidance published today NICE has recommended adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira; Remsima, Napp Pharmaceuticals)1, certolizumab pegol (Cimzia, UCB Pharma) and golimumab (Simponi, Merck Sharp & Dohme) 2 – known as TNF-alpha inhibitors – for treating some types of inflammatory arthritis that affect the spine.

As well as re-affirming previous NICE guidance recommending adalimumab, etanercept and golimumab as treatment options for adults with ankylosing spondylitis, the draft guidance also now recommends infliximab and certolizumab pegol as additional treatment options for adults with anklylosing spondylitis.

Non-radiographic axial spondyloarthritis is also covered by the draft guidance and adalimumab, certolizumab pegol and etanercept are provisionally recommended as treatment options for adults with this condition.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-draft-guidance-recommends-treatments-for-types-of-arthritis-that-affect-the-spine